Thirty-year trends in outcomes of percutaneous coronary interventions in diabetic patients

Mayo Clinic Proceedings

Volumn 88, Issue 1, 2013, Pages 22-30

  Singh, Mandeep ^a   Holmes, David R ^a   Gersh, Bernard J ^a   Frye, Robert L ^a   Lennon, Ryan J ^a   Rihal, Charanjit S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; LONG TERM SURVIVAL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84872947096     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2012.09.014     Document Type: Article

References (26)

1. Singh M, Rihal CS, Gersh BJ, et al. Twenty-five-year trends in in-hospital and long-term outcome after percutaneous coronary intervention: a single-institution experience. Circulation. 2007;115(22):2835-2841.
2. Ortolani P, Balducelli M, Marzaroli P, et al. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. Circulation. 2008;117(7):923-930.
3. Prasad A, Rihal CS, Lennon RJ, Wiste HJ, Singh M, Holmes DR Jr. Trends in outcomes after percutaneous coronary intervention for chronic total occlusions: a 25-year experience from the Mayo Clinic. J Am Coll Cardiol. 2007;49(15):1611-1618.
4. Singh M, Peterson ED, Roe MT, et al. Trends in the association between age and in-hospital mortality after percutaneous coronary intervention: National Cardiovascular Data Registry experience. Circ Cardiovasc Interv. 2009;2(1):20-26.
5. SinghM,MathewV,Garratt KN, et al. Effect of age on the outcome of angioplasty for acute myocardial infarction among patients treated at the Mayo Clinic. Am J Med. 2000;108(3):187-192.
6. Singh M, Reeder GS, Ohman EM, et al. Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? an Angiographic Trials Pool data experience. J Am Coll Cardiol. 2001;38(3):624-630.
7. BARI 2D Study Group; Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-2515.
8. Singh M, Rihal CS, Lennon RJ, Spertus J, Rumsfeld JS, Holmes DR Jr. Bedside estimation of risk from percutaneous coronary intervention: the new Mayo Clinic risk scores. Mayo Clin Proc. 2007;82(6):701-708.
9. Mathew V, Gersh BJ, Williams BA, et al. Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004;109(4):476-480.
10. Mathew V, Frye RL, Lennon R, Barsness GW, Holmes DR Jr. Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycemic agents. Am J Cardiol. 2004;93(4):399-403.
11. Singh M, Lennon RJ, Holmes DR Jr, Bell MR, Rihal CS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002; 40(3):387-393.
12. Syed AI, Ben-Dor I, Li Y, et al. Outcomes in diabetic versus nondiabetic patients who present with acute myocardial infarction and are treated with drug-eluting stents. Am J Cardiol. 2010; 105(6):819-825.
13. Singh M, Rihal CS, Roger VL, et al. Comorbid conditions and outcomes after percutaneous coronary intervention. Heart. 2008;94(11):1424-1428.
14. Singh M, Reeder GS, Jacobsen SJ, Weston S, Killian J, Roger VL. Scores for post-myocardial infarction risk stratification in the community. Circulation. 2002;106(18):2309-2314.
15. Kuntz RE. Importance of considering atherosclerosis progression when choosing a coronary revascularization strategy: the diabetes-percutaneous transluminal coronary angioplasty dilemma. Circulation. 1999;99(7):847-851.
16. Sobel BE, Frye R, Detre KM; Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2003;107(4):636-642.
17. published correction appears in Circulation. 2003;108(4):500
18. Sobel BE, Woodcock-Mitchell J, Schneider DJ, Holt RE, Marutsuka K, Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97(22):2213-2221.
19. Singh M, Rihal CS, Berger PB, et al. Improving outcome over time of percutaneous coronary interventions in unstable angina. J Am Coll Cardiol. 2000;36(3):674-678.
20. Jaber WA, Lennon RJ, Mathew V, Holmes DR Jr, Lerman A, Rihal CS. Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. J Am Coll Cardiol. 2005;46(8):1473-1478.
21. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355(9200):253-259.
22. published correction appears in Lancet. 2000;356(9232):860
23. Colhoun HM, Betteridge DJ, Durrington PN, et al CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696.
24. Farkouh ME, Dangas G, Leon MB, et al. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) Trial. Am Heart J. 2008;155(2):215-223.
25. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-591.
26. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348(5):383-393.